{"id":"e2-patch-antagonist","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin irritation at patch site"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Breast tenderness"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination approach provides estrogen replacement via transdermal delivery while simultaneously antagonizing estrogen receptors, potentially modulating hormone-dependent pathways. The dual mechanism may be designed to achieve therapeutic benefits in conditions where estrogen replacement alone is insufficient or where receptor antagonism provides additional benefit.","oneSentence":"An estradiol (E2) transdermal patch that delivers estrogen while blocking estrogen receptor signaling through an antagonist component.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:35:51.960Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Menopausal symptoms (investigational combination approach)"}]},"trialDetails":[{"nctId":"NCT04671966","phase":"PHASE4","title":"Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction","status":"UNKNOWN","sponsor":"The University of Texas at Arlington","startDate":"2018-09-13","conditions":"Heart Diseases, Left Ventricular Dysfunction","enrollment":100},{"nctId":"NCT03236545","phase":"NA","title":"Menopause Effects on Vascular Function","status":"COMPLETED","sponsor":"University of Delaware","startDate":"2016-07-01","conditions":"Cardiovascular Risk Factor","enrollment":48},{"nctId":"NCT03112226","phase":"NA","title":"Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2018-02-07","conditions":"Cognitive Impairment, Estrogen Deficiency, Menopause","enrollment":19},{"nctId":"NCT00826839","phase":"PHASE4","title":"Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2009-01","conditions":"Infertility","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":83,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Climara®","Ganirelix acetate injection®"],"phase":"marketed","status":"active","brandName":"E2 patch/antagonist","genericName":"E2 patch/antagonist","companyName":"Weill Medical College of Cornell University","companyId":"weill-medical-college-of-cornell-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"An estradiol (E2) transdermal patch that delivers estrogen while blocking estrogen receptor signaling through an antagonist component. Used for Menopausal symptoms (investigational combination approach).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}